Regulatory Q&A Forum
Ask questions, share knowledge, and get help from the regulatory community
For non-EU medical device manufacturers, selecting an EU Authorised Representative (AR) is a critical step for market access under the Medical Device Regulation (MDR). Beyond simply fulfilling a legal...
When developing a long-range strategic plan for a novel Class II diagnostic device, such as an acute kidney injury test system falling under 21 CFR 862.1220, what are the critical non-financial resour...
For UK-based medical device manufacturers, appointing an EU Authorized Representative (AR) is a critical step for placing products on the European Union market. While direct costs vary, understanding ...
As the United Kingdom’s medical device regulatory framework continues to evolve, what are the key practical and strategic considerations for non-UK manufacturers when selecting or re-assessing their U...
For a cosmetic brand preparing for the significant EU regulatory updates anticipated for 2026, what does a comprehensive due diligence process for selecting a new Responsible Person (RP) entail, beyon...
When preparing a premarket submission for a connected medical device, such as an integrated continuous glucose monitoring system (iCGM) under 21 CFR 862.1355 or a novel diagnostic test system, how can...
When a non-EU manufacturer plans to place a medical device on the European market, appointing an EU Authorized Representative (AR) is a mandatory step under the Medical Device Regulation (MDR). While ...
Under the Modernization of Cosmetics Regulation Act (MoCRA), the role and responsibilities of a U.S. Agent for foreign cosmetic facilities have expanded significantly beyond serving as a simple point ...
With new regulatory expectations for the European cosmetics market anticipated around 2026, how should a non-EU brand strategically evaluate and select a Responsible Person (RP) to ensure not just mar...
As non-EU manufacturers prepare for the EU AI Act, many are exploring whether their existing GDPR Article 27 Representative can also serve as their Authorised Representative for AI systems. While cons...
When budgeting for an EU Authorized Representative (AR) under the AI Act, how can non-EU manufacturers accurately forecast costs when service fees are not standardized? The pricing for an AR can vary ...
Beyond the basic requirement that foreign medical device establishments must designate a U.S. Agent, what are the detailed responsibilities and critical qualifications that define this role? FDA's reg...
When budgeting for European Union market compliance for 2026, many medical device manufacturers consider outsourcing the Person Responsible for Regulatory Compliance (PRRC) role. While this 'as a Serv...
For non-EU based medical device and SaMD companies preparing their compliance strategies for 2026, what is a comprehensive framework for selecting a GDPR Article 27 Representative that moves beyond a ...
As the European Union's regulatory landscape grows more complex with frameworks like the Medical Device Regulation (MDR) and broad-reaching initiatives such as the Carbon Border Adjustment Mechanism (...
With the implementation of the Modernization of Cosmetics Regulation Act (MoCRA), what are the precise operational and legal requirements for an entity serving as an FDA U.S. Agent for a foreign cosme...
When budgeting for EU MDR compliance into 2026, how can medical device manufacturers forecast the cost of engaging a "Person Responsible for Regulatory Compliance (PRRC) as a Service"? While specific ...
For non-EU manufacturers planning their European market strategy for 2026, what are the key service and portfolio factors that determine the cost of appointing a REACH Only Representative (OR)? Rather...
Under the Modernization of Cosmetics Regulation Act (MoCRA), foreign cosmetic facilities must designate a U.S. Agent to serve as a point of contact for the FDA. While this is a mandatory requirement f...
Under the Modernization of Cosmetics Regulation Act (MoCRA), foreign cosmetic facilities are required to designate a U.S. Agent for FDA registration and as a point of contact. This new mandate raises ...